Replies to post #37865 on Cytogenix (fka CYGX)

[gdepc]

david you are far from correct

you said
GE is not involved with the company, but only supplies them with product which they use in their research

CytoGenix and GE Healthcare Ink BioDefense Support Agreement
12/27/2005 4:18:01 PM

HOUSTON, Dec 27, 2005 (BUSINESS WIRE) -- CytoGenix, Inc. ( CYGX ) announced today the signing of a contract with the Fast Trak BioDefense group of GE Healthcare, a unit of General Electric Company ( GE ).

GE Healthcare's Fast Trak BioDefense group has a diverse staff of highly qualified technical and regulatory experts who will collaborate with CytoGenix in seeking, obtaining and executing bio-defense related federal contracts.

Frank Vazquez, CytoGenix, Inc. Executive Vice President and COO commented, "Our association with GE Healthcare, a $14 Billion entity of GE, as partners in competing for federal research projects sends a very positive message to grant reviewers and granting agencies at the Department of Homeland Security, the Department of Defense and the Department of Health and Human Services. We are very excited about this relationship and expect to see very positive results soon."

Dr. Sandy Weinberg, Senior Director, Fast Trak BioDefense GE Healthcare commented, "CytoGenix's innovative DNA vaccine and antimicrobial technology can be applied to many critical needs in bio-defense. The company has an excellent team of scientists, and we expect with that with our assistance we can attain substantial results."

About GE Healthcare: GE Healthcare is a $14 billion unit of General Electric Company ( GE ) that is headquartered in the United Kingdom. Worldwide, GE Healthcare employs more than 42,500 people committed to serving healthcare professionals and their patients in more than 100 countries. For more information about GE Healthcare, visit the company's website at www.gehealthcare.com.

About CytoGenix: CytoGenix, Inc. is a Houston-based biopharmaceutical company that develops and markets innovative products and services based on its proprietary ssDNA expression technology. The company has developed a breakthrough synthetic process for large-scale production of high purity DNA at a fraction of the cost of traditional fermentation methods. CytoGenix currently has one issued US patent and 41 international or US pending patent applications claiming methods and materials in connection with this platform technology.

gdepc

[holycow]

David, I apologize if my remarks were too broadly blaming. I happen to feel that the officers are often criticized unfairly when the share price is down. I am sorry that I have not been more forthcoming with useful information. I felt freer to do so when it involved my own wild speculation about developments. Now I feel a bit more constrained. My long standing, very positive interpretation of developments continues despite the fact that my speculation has been wrong many times in the past. To react to the concerns of another poster as well, I am far from 100% certain that my understanding is correct. Can I really be sure that I am seeing things correctly? Have to cut it now.